培米替尼中国上市了吗？

Cholangiocarcinoma is a highly malignant tumor with strong invasiveness and poor prognosis. Many patients have lost the chance of surgery when diagnosed. Systemic treatment options for advanced cholangiocarcinoma are extremely scarce. The objective response rate (ORR) of first-line standard chemotherapy is only 15%-26%. Drug resistance often occurs, and there is no standard second-line treatment option. There is an urgent need for new treatment options to improve patient survival. Pemetinib is a small molecule kinase inhibitor targeting FGFR1, 2 and 3 with an IC50 value of less than 2nM. Pemetinib also inhibited FGFR4 in vitro at concentrations approximately 100-fold higher than those inhibiting FGFR1, 2, and 3. Activation of FGFR amplification and fusion results in constitutive activation of FGFR, thereby inhibiting FGFR1-3 phosphorylation and signaling and reducing cell viability.

Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Pemetinib exhibits antitumor activity in mouse xenograft models of human tumors with alterations in FGFR1, FGFR2, or FGFR3, resulting in constitutive FGFR activation, including cholangiocarcinoma xenograft models in patients expressing oncogenic FGFR2-Transformer-2 beta homolog (TRA2b) fusion proteins.

In April 2020, the FDA accelerated approval of the marketing application for the targeted drug pemetinib for the treatment of patients with previously treated advanced cholangiocarcinoma with FGFR2 gene fusion/rearrangement. As the first targeted drug for cholangiocarcinoma, pemetinib is expected to change the clinical treatment landscape for patients with cholangiocarcinoma.

Has pemetinib been launched in China?

It is understood that it has not been officially launched in China yet. Patients in need can contact regular domestic overseas medical service institutions (Medical Companion Travel) to purchase the version launched abroad!

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: